Muscular Dystrophy UK has sent a written evidence submission to the House of Commons Science and Technology Committee’s inquiry on the preparations for a no-deal Brexit in relation to science and innovation.
What the submission included
The points made in the submission took into account concerns of the effect on patients accessing medicines after Brexit and UK access to research funding.
We took into consideration the Government’s guidance documents published in September 2018 which specifically focused on the no-deal scenario.
The submission included comments and concerns on:
- regulation of new medicines and whether there will be close links with the European Medicines Agency
- UK patients accessing clinical trials
- UK access to current and future EU-wide research funding and innovation programmes
- retaining and attracting the best researcher talent from the EU
Uncertainty of no-deal
The lack of clarity and certainty in a no-deal Brexit could have significant and concerning implications for patients and their families, clinicians and researchers in the short and long term.
We highlighted that time is of the essence for administering many treatments for rare conditions, such as for muscular dystrophy and neuromuscular conditions, and that any delays to making potentially ground-breaking life extending or progression slowing treatments available are devastating for patients and their families.
We reiterated the need for reform of the treatment approval process within the UK, and raised concerns that a no-deal Brexit could add another layer of delays for UK patients.